Evidence map›Paper›PMID 35521291›Full record

ArticleSchizophrenia research. Cognition2022

Examining the association of life course neurocognitive ability with real-world functioning in schizophrenia-spectrum disorders.

Sylvia Romanowska, Michael W Best, Christopher R Bowie, Colin A Depp, Thomas L Patterson, David L Penn, Amy E Pinkham, Philip D Harvey

Abstract read
In one paragraph

Article in Schizophrenia research. Cognition, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Ten years ofSchizophrenia research. Cognition · 2024
    Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sylvia RomanowskaDepartment of Psychological Science, University of Toronto Scarborough, Toronto, ON, Canada.
Michael W BestDepartment of Psychological Science, University of Toronto Scarborough, Toronto, ON, Canada.
Christopher R BowieDepartment of Psychology, Queen's University, Kingston, ON, Canada.
Colin A DeppDepartment of Psychiatry, UCSD Medical Center, La Jolla, CA, United States.
Thomas L PattersonDepartment of Psychiatry, UCSD Medical Center, La Jolla, CA, United States.
David L PennDepartment of Psychology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Amy E PinkhamDepartment of Psychology, University of Texas at Dallas, Dallas, TX, United States.
Philip D HarveyUniversity of Miami Miller School of Medicine, Miami VA Healthcare System, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is considerable variability in neurocognitive functioning within schizophrenia-spectrum disorders, and neurocognitive performance ranges from severe global impairment to normative performance. Few investigations of neurocognitive clusters have considered the degree to which deterioration relative to premorbid neurocognitive abilities is related to key illness characteristics. Moreover, while neurocognition and community functioning are strongly related, understanding of the sources of variability in the association between these two domains is also limited; it is unknown what proportion of participants would over-perform or under-perform the level of functioning expected based on current neurocognitive performance vs. lifelong attainment. This study examined data from 954 outpatients with schizophrenia-spectrum disorders across three previous studies. Neurocognition, community functioning, and symptoms were assessed. Neurocognitive subgroups were created based on current neurocognition, estimated premorbid IQ, and degree of deterioration from premorbid using z-score cut-offs; functional subgroups were created with cluster analysis based on the Specific Level of Functioning Scale and current neurocognition. The sample was neurocognitively heterogeneous; 65% displayed current neurocognitive impairment and 84% experienced some level of deterioration. Thirty percent of our sample was relatively higher functioning despite significant neurocognitive impairment. Individuals with better community functioning, regardless of neurocognitive performance, had lower symptom severity compared to those with worse functioning. These results highlight the variability in neurocognition and its role in functioning. Understanding individual differences in neurocognitive and functional profiles and the interaction between prior and current cognitive functioning can guide individualized treatment and selection of participants for clinical treatment studies.

Indexed as

Cluster analysisFunctioningNeurocognitionPsychosisSchizophrenia

Identifiers

PMID35521291
PMCPMC9062312

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.